4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Purity >98.5% (HPLC) Lenvatinib Mesylate Intermediate Factory
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates With High Pure
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Ingoa matū | 4-Chloro-7-Methoxyquinoline-6-Carboxamide |
Nga kupu taurite | 4-Chloro-7-Methoxy-6-Quinolinecarboxamide;Lenvatinib poke 12;Lenvatinib poke B;Lenvatinib poke LFS-B |
Tau CAS | 417721-36-9 |
Tau CAT | RF-PI1971 |
Tūnga Taonga | I roto i te Raarangi, Te Whakaputa Whakanui 50MT / Tau |
Tātai rāpoi | C11H9ClN2O2 |
Taumaha rāpoi | 236.65 |
Te Whakarewa | >205℃ (tikuri) |
Kiato | 1.380±0.060 g/cm3 |
Waitohu | Ruifu Chemical |
Tūemi | Whakatakotoranga |
Te ahua | Paura-White ki te Paura Kowhai Maama |
Te Maama / Tikanga Tatauria | >98.5% (HPLC) |
Ngaronga i te whakamaroke | <0.50% |
Te toenga i runga i te mura | <0.50% |
Nga poke katoa | <1.50% |
Proton NMR Spectrum | He rite ki te Hanganga |
Paerewa Whakamatau | Paerewa hinonga |
Whakamahinga | Takawaenga o Lenvatinib Mesylate (CAS: 857890-39-2) |
Mōkī: Pounamu, Peeke konumohe konumohe, 25kg / Kaata Drum, kia rite ranei ki te hiahia a te kaihoko
Tikanga Rokiroki:Whakaorangia i roto i nga ipu kua hiri ki te waahi makariri me te maroke;Tiaki i te marama me te makuku
Ko te 4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) te nuinga o te whakamahi hei takawaenga o Lenvatinib Mesylate (CAS: 857890-39-2).I whakawhanakehia e Eisai Inc., ko te lenvatinib mesylate he aukati vascular endothelial growth factor receptor (VEGF) he mahi ki te VEGF subtypes 1, 2, me 3 a i whakaaetia e te FDA i te tau 2015 mo te maimoatanga o te mate pukupuku thyroid rerekee kei te rohe. he auau, he metastatic, he ahu whakamua ranei, kaore i aro ki te maimoatanga iodine radioactive.I te marama o Haratua 2016, i whakaaetia e te FDA te rongoa hei rongoa whakakotahi me te everolimus mo te maimoatanga o te mate pukupuku o te pukupuku renal.Na te mea ko te VEGF (me nga kaiwhakawhiwhi take tipu fibroblast, e mohiotia ana ko FGFRs) e whakaarohia ana ka whai waahi ki nga huarahi tohu tohu cardiovascular, ko te VEGF2R me te aukati FGFR te whakaaro ko nga tikanga kei muri i te paanga tuatahi o te lenvatinib mesylate, ko te whakaheke toto.